Donate

Estimating the cost of RSV disease and cost-effectiveness of RSV prevention measures in multiple Gavi-eligible countries

Respiratory syncytial virus (RSV) is a leading cause of acute lower respiratory tract infections in young children. Two preventive interventions for RSV—a maternal vaccine and long-acting monoclonal antibodies (mAbs) delivered to infants—are recommended by the World Health Organization. When countries consider introducing new vaccines, immunization program cost and affordability are key questions.

To address some of these questions, the University Medical Centre Utrecht and PATH conducted studies as part of a multi-country collaboration called the RSV GOLD III-Health Economics Study to evaluate the economic burden of RSV disease (or cost of illness) and the impact and cost-effectiveness of RSV prevention (e.g., via maternal immunization or long-acting monoclonal antibodies) in Gavi, the Vaccine Alliance-eligible countries. The estimates will help inform policy decisions in low- and middle-income countries where maternal immunization-preventable diseases often hit hardest.

Find here links to the peer-reviewed journal articles and select fact sheets summarizing the research. [Note: Some publications and fact sheets are forthcoming.]

Corporate author(s): University Medical Centre Utrecht, PATH

Publication date: February 2026

Available materials

  1. English

    1. Estimating the cost of RSV and other acute respiratory infections in Nigeria 247.2 KB PDF

      Fact sheet

  2. English

    1. Assessing the cost of illness of RSV and non-RSV acute respiratory infections in Nepali children

      Article published in Journal of Global Health
    2. Cost-effectiveness of introducing a maternal vaccine or long-acting monoclonal antibody to prevent infant respiratory syncytial virus disease in Nepal

      Article published in Journal of Global Health
    3. Estimating the economic burden of respiratory syncytial virus infection among children <2 years old seeking care in North-West Nigeria

      Article published in Journal of Global Health
    4. Cost-effectiveness of respiratory syncytial virus prevention strategies in Mozambique: a modelling study

      Article published in Journal of Global Health Economics and Policy
    5. Estimating the economic burden of respiratory syncytial virus infection among children <2 years old receiving care in Maputo, Mozambique

      Article published in Journal of Global Health